The Role of a Clinical Pharmacist in Lifestyle Modification in Type 2 Diabetic Patients With Peripheral Neuropathy

Hawler Medical University200 enrolled

Overview

The aims of this study are to determine the prevalence of diabetic peripheral neuropathy among the diabetic patients, to determine the association between the clinical profiles of the diabetic patients (diabetes type, diabetes duration, HbA1c, body mass index, hypertension, total cholesterol) and the diabetic peripheral neuropathy DPN and the rational poly pharmacy used to control pain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

200

Conditions

Diabetic Peripheral Neuropathy

Interventions

Diabetic patients with neuropathyOTHER

Lifestyle modification will be assessed using summary of diabetes self-care activity

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion criteria 1. Aged 18 years or older. 2. Both sex. 3. Diagnosed with type 2 diabetes at least one year previously. 4. Took at least one prescribed medication for diabetes. 5. Diagnosed as diabetic peripheral neuropathy based on clinical Exclusion Criteria: 1. History of alcohol consumption. 2. Thyroid gland disorder. 3. Any kidney disorder. 4. Any conditions that could confound assessment of pain due to diabetic peripheral neuropathy. 5. Have foot injury or open sore. 6. Pregnant females or who plan to become pregnant during the study period. 7. Any serious medical condition that might prevent completion or hinder compliance with exercise. \-

Locations (1)

Prof. Kawa Dizaye

Erbil, Iraq

RECRUITING

Outcomes

Primary Outcomes

Estimating Summary of diabetes self-care activity (SDSCA)

Assessing Lifestyle modification by summary of diabetes self-care activity (SDSCA) at baseline visit and after three months for both Intervention patients and usual care group Increases in the means of the items of the scale as Exercise, Blood sugar testing, Specific diet and Foot care in the intervention group.

Time frame: Three months

Adherence to treatment according to Morisky scale

Morisky scale is used to assess medication adherence at baseline visit and after three months for both Intervention patients and usual care group. Improving the patient medication adherence behavior in the intervention group patients

Time frame: Three months

Douleur Neuropathique 4 (DN4), Neuropathic Pain Scale (NPS),

Reduction in the percent of response of patients feeling; electric shock, tingling, and pin needle after the lifestyle modification in the intervention group.

Time frame: Three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.